ABSTRACT
Worldwide, neurocysticercosis is the most common parasitic infection of the brain. In Latin America alone, it is estimated that over 400,000 people have symptomatic neurocysticercosis (1). The burden of neurocysticercosis is considerable. In Peru, about one in 2000 adults have seizures due this infection and 25% of adult-onset epilepsy in Latin America is due to neurocysticercosis (1,2). Annual economic costs from neurocysticercosis have been estimated to be about $85 million in Mexico and Brazil and $9 million in the United States (3).
